SEC Filing Summary: Leap Therapeutics, Inc. (LPTX)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. Leap Therapeutics, Inc. is a biopharmaceutical company developing biomarker-targeted antibody therapies for cancer. Its lead clinical-stage program is sirexatamab (DKN-01), a monoclonal antibody targeting DKK1. The company has no approved products and has not generated product revenue. As of June 30, 2025, the company has 41,439,529 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(16.6) million | $(32.1) million | $(33.9) million |
| Operating Expenses | $16.9 million | $32.8 million | $36.1 million |
| Cash and Equivalents | $18.1 million (End of Period) | $18.1 million (End of Period) | $78.5 million (End of Period) |
| Cash Used in Operations (YTD) | N/A | $(29.0) million | $(29.2) million |
| Accumulated Deficit | $(499.4) million | $(499.4) million | $(467.4) million |
Debt and Liquidity: The company has no long-term debt but holds an insurance financing agreement with an outstanding principal of $0.2 million. Current liabilities total $14.3 million, primarily accounts payable and accrued expenses (including $3.5 million in severance accruals).
Material Changes vs. Prior Period
- Restructuring Charges: The company incurred $4.5 million in restructuring charges during Q2 2025, compared to none in the prior year. This resulted from a workforce reduction impacting approximately 75% of the workforce, including the departure of the COO, CSO, CMO, and CMO.
- Expense Reduction: Despite restructuring charges, total operating expenses decreased by $4.4 million in Q2 2025 compared to Q2 2024. Research and Development (R&D) expenses dropped $7.3 million, driven by reduced clinical trial costs, lower manufacturing costs, and headcount reductions.
- Cash Position: Cash and cash equivalents declined significantly from $47.2 million at year-end 2024 to $18.1 million at June 30, 2025, reflecting a net cash burn of $29.1 million over the first half of the year.
- Strategic Shift: The company announced the completion of the DeFianCe clinical trial and the wind-down of its R&D activities for sirexatamab and FL-501 to conserve cash.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least 12 months from the issuance date due to the need for additional capital and the lack of revenue.
- Strategic Alternatives: The Board has engaged Raymond James & Associates to explore strategic alternatives, including mergers, asset sales, or licensing agreements for sirexatamab and FL-501. There is no assurance a transaction will be completed.
- Clinical Update: Updated data from the DeFianCe study showed sirexatamab demonstrated a statistically significant benefit on overall response rate and progression-free survival in specific patient subgroups. Final data is being prepared for presentation.
- Risks: Key risks include the inability to secure additional financing, failure to complete a strategic transaction, and the potential need to wind up operations and liquidate if funding is not secured.
Investor Verification Checklist
- Cash Runway: Verify the current cash burn rate against the $18.1 million cash balance to estimate the remaining operational runway without new financing.
- Strategic Process Status: Monitor for updates on the engagement with Raymond James and any potential offers or partnership announcements regarding the sirexatamab asset.
- Severance Obligations: Confirm the timing and actual cash outflow for the $3.5 million accrued severance liability, which is expected to be paid in Q3 and Q4 2025.
- Listing Compliance: Review the company's status regarding Nasdaq Capital Market listing requirements, as the filing notes risks related to regaining compliance.
- Asset Valuation: Assess the market value of the sirexatamab and FL-501 assets given the decision to wind down internal development and seek external partners.